Novel Prodrugs for Selective Anticancer Therapy

The technology relates to the anticancer prodrugs that can be activated by the two key enzymes over expressed in metastatic cancer cells. Background: Anticancer drug sales exceeded $50 billion worldwide in 2009 with impressive growth; however, lack of target selectivity is a major challenge in cancer treatment. The limitation of current chemotherapy is in delivering high enough concentrations ofcytotoxic drug to the target site in order to completely eradicate the tumor without harming healthy cells. Therefore, a technology that can enhance target selectivity would significantly improve clinical outcomes as well as quality of life forpatients and thus have the potential to create novel drugs that can take over and dominate the market. Technology Overview: Dr. Nobuhide Ueki and Dr. Michael Hayman at Stony Brook University have developed novel methods and compositions to make anticancer prodrugs by conjugating unique dual-substrate biochemical modules to known or novel chemotherapeutic drugs. Therequirement of sequential activation by two independent key enzymes acting in tumor cells makes the prodrugs highly selective, resulting in fewer side effects compared to existing anticancer drugs in clinical use. In addition, these novel prodrugshave been shown to be much more stable and resistant to non-specific activation by ubiquitous proteases in cytoplasm or plasma than existing prodrugs. Advantages: Better selectivity with minimal adverse effects l Reduced nonspecific activation by ubiquitous proteases in cytoplasm or plasma l Ability to "repackage" existing generic chemotherapeutic drugs to improve selectivity Applications: Anticancer drug therapy l Prodrug formulation Intellectual Property Summary: US Utility pending (#14/428,501) Stage of Development: Proof of concept data is available. Licensing Potential: We seek to develop and commercialize, by an exclusive or non-exclusive license agreement and/or sponsored research, with a company active in the area. Licensing Status: Available for License Additional Information: Further reading: Ueki et al., 4:2735, 2013 Anticancer drug therapy l Chemotherapeutic prodrugs l Cancer , ,
Patent Information:
Technology/Start-up ID: